ChemoCentryx Inc (NASDAQ:CCXI)
| 13.61 Data as of May 17 |  -0.16 / -1.16%Today’s Change | 9.19 Today|||52-Week Range 16.95 | +24.41% Year-to-Date |
Latest CCXI News | Press Releases
| Wider-than-Expected Loss at ChemoCentryx - Analyst Blog May 14 / Zacks.com |
Today’s Trading
| Previous close | 13.77 |
| Today’s open | 13.78 |
| Day’s range | 13.44 - 13.78 |
| Volume | 28,280 |
| Average volume (3 months) | 121,841 |
| Market cap | $580.0M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -2.73% |
| Earnings growth (this year) | +2.89% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -82.89% |
| P/E ratio | NM |
| Price/Sales | 71.48 |
| Price/Book | 4.48 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| OREXOrexigen Therapeutic... | -0.01 | -0.17% |
| LGNDLigand Pharmaceutica... | +1.32 | +4.95% |
| ICPTIntercept Pharmaceut... | +1.27 | +3.97% |
| MACKMerrimack Pharmaceut... | +0.04 | +0.73% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Last reporting date | May 14, 2013 |
| EPS forecast (this quarter) | -$0.27 |
| Annual revenue (last year) | $5.4M |
| Annual profit (last year) | -$39.9M |
| Net profit margin | -736.13% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Thomas J. Schall, PhD |
CFO, Secretary & Senior VP-Investor Relations Susan M. Kanaya |
Corporate headquarters Mountain View, California |
Forecasts
